CalmanPhilipPrussinMD

Chief Scientific Officer, Areteia Therapeutics

Dr. Prussin is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

Office
Knopp Biosciences-Rockville
North Bethesda, MD 20852
Phone+1 412-488-1776

National Institutes of Health Clinical CenterFellowship, Allergy and Immunology, 1988 - 1994
University of Southern California/Los Angeles General Medical Center (USC/LA General)Residency, Internal Medicine, 1984 - 1987
Keck School of Medicine of the University of Southern CaliforniaClass of 1984

PubMed

4 citations
Safety and Efficacy of Dexpramipexole in Eosinophilic Asthma (EXHALE): A randomized controlled trial.
Salman Siddiqui, Sally E Wenzel, Michael E Bozik, Donald G Archibald, Steven I Dworetzky
The Journal of Allergy and Clinical Immunology. 2023-11-01
7 citations
Urine eosinophil-derived neurotoxin: A potential marker of activity in select eosinophilic disorders.
Michelle A Makiya, Paneez Khoury, Fei Li Kuang, Alexis Dominique Mata, Sana Mahmood
Allergy. 2023-01-01
64 citations
Dexpramipexole depletes blood and tissue eosinophils in nasal polyps with no change in polyp size.
Tanya M. Laidlaw, Calman Prussin, Reynold A. Panettieri, Stella E. Lee, Berrylin J. Ferguson
The Laryngoscope. 2019-02-01

Journal Articles

Safety and Efficacy of Dexpramipexole in Eosinophilic Asthma (EXHALE): A randomized controlled trial
Salman Siddiqui, BM, FRCP, PhD,a Sally E. Wenzel, MD,b Michael E. Bozik, MD,c Donald G. Archibald, MPhil,c Steven I. Dworetzky, PhD,c James L. Mather, BS,c Randall Kil..., Journal of Allergy and Clinical Immunology, 11/2023

Knopp Biosciences Presents New Phase 2 Data at AAAAI 2022 Demonstrating That Oral Dexpramipexole Improves Airflow Obstruction as Measured by Forced Expiry Volume (FEV1), Largely Through Its Effect on Forced Vital Capacity (FVC)February 28th, 2022
Knopp Biosciences Reports Positive Results from the Phase 2 EXHALE Trial of Oral Dexpramipexole in Moderate-to-Severe Eosinophilic Asthma at ATS 2021May 17th, 2021
Knopp Biosciences to Present Clinical Data for Dexpramipexole at 11th Biennial Symposium of the International Eosinophil SocietyJuly 9th, 2019
Join now to see all

Highly Differentiated Il5+ TH2 Cells In Food Allergy And Eosinophilic GI DiseaseNational Institute Of Allergy And Infectious Diseases2010–2011
Functional And Epigenetic Analysis Of TH2 HeterogeneityNational Institute Of Allergy And Infectious Diseases2010–2011
T Cell Pathogenesis Of Food AllergyNational Institute Of Allergy And Infectious Diseases2009
Developmental Immunotherapeutics Of Allergic DiseasesNational Institute Of Allergy And Infectious Diseases2009
Memory T Cell Responses To Food AllergyNational Institute Of Allergy And Infectious Diseases2008
Developmental Immunotherapeutics Of Allergic DiseasesNational Institute Of Allergy And Infectious Diseases2008
Induction And Inhibition Of Ige-Mediated Hypersensitivity To VaccinesNational Institute Of Allergy And Infectious Diseases2007
Developmental Immunotherapeutics For Allergic Diseases And AsthmaNational Institute Of Allergy And Infectious Diseases2007
Developmental Immunotherapeutics For Allergic Diseases ANational Institute Of Allergy And Infectious Diseases2002–2006
Cytokine Profiles In Asthma And Allergic DiseasesNational Institute Of Allergy And Infectious Diseases2002–2006
Developmental Immunotherapeutics-Allergic Disease/AsthmaNational Institute Of Allergy And Infectious Diseases2005
Immunotherapeutics For Allergic Diseases And AsthmaNational Institute Of Allergy And Infectious Diseases2003